oalib

Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99

Submit

Any time

2019 ( 86 )

2018 ( 173 )

2017 ( 167 )

2016 ( 279 )

Custom range...

Search Results: 1 - 10 of 130400 matches for " Bellia V "
All listed articles are free for downloading (OA Articles)
Page 1 /130400
Display every page Item
Apertura della I sessione
Francesco Bellia
Aestimum , 2007,
Abstract: Apertura della I sessione
Cyclosporine-Associated Nephrotoxicity  [PDF]
Maria Delia Colombo, Renata Perego, Gilberto Bellia
Open Journal of Nephrology (OJNeph) , 2013, DOI: 10.4236/ojneph.2013.33030
Abstract:

Cyclosporine (CsA) has revolutionized transplant medicine and is currently one of the most important immunosuppressive agents for a wide range of organ transplantations and of autoimmune and inflammatory diseases, such as rheumatoid arthritis, uveitis, psoriasis, and atopic dermatitis. Renal impairment represents the main limitation to CsA long-term continuous therapy. However, it has been shown that nephrotoxicity is associated with longer treatment duration, larger cumulative doses and higher daily dose of CsA. With low dose regimens (<5 mg/kg/day), stable serum creatinine levels have been observed up to 15-20 years after kidney transplantation. Intermittent therapy may offer a good therapeutic strategy to limit long-term renal dysfunction, given the fact that renal structural changes are dose- and time-dependent. The best predictor of permanent renal damage is a persistent increase in serum creatinine level one month after treatment withdrawal. In patients with autoimmune diseases, the percentage increase in serum creatinine above baseline value during CsA therapy has been shown to predict CsA-induced nephropathy. Before CsA therapy initiation, patients should undergo a thorough baseline evaluation including laboratory assessments, in particular electrolytes, serum creatinine, and urea levels. Furthermore, patients should be evaluated for factors that might increase the risk of nephrotoxicity, such as obesity, older age, hypertension, concomitant use of nephrotoxic drugs, and pre-existing renal conditions. In the present paper, CsA-induced nephropathy will be reviewed in terms of pathophysiology, pathologic and clinical findings, and strategies for prevention and management.

Lung penetration and patient adherence considerations in the management of asthma: role of extra-fine formulations
Scichilone N, Spatafora M, Battaglia S, Arrigo R, Benfante A, Bellia V
Journal of Asthma and Allergy , 2013, DOI: http://dx.doi.org/10.2147/JAA.S14743
Abstract: ng penetration and patient adherence considerations in the management of asthma: role of extra-fine formulations Review (1144) Total Article Views Authors: Scichilone N, Spatafora M, Battaglia S, Arrigo R, Benfante A, Bellia V Published Date January 2013 Volume 2013:6 Pages 11 - 21 DOI: http://dx.doi.org/10.2147/JAA.S14743 Received: 02 November 2012 Accepted: 10 December 2012 Published: 24 January 2013 Nicola Scichilone, Mario Spatafora, Salvatore Battaglia, Rita Arrigo, Alida Benfante, Vincenzo Bellia Dipartimento di Biomedicina e Medicina Interna e Specialistica, Sezione di Pneumologia, University of Palermo, Palermo, Italy Abstract: The mainstay of management in asthma is inhalation therapy at the target site, with direct delivery of the aerosolized drug into the airways to treat inflammation and relieve obstruction. Abundant evidence is available to support the concept that inflammatory and functional changes at the level of the most peripheral airways strongly contribute to the complexity and heterogeneous manifestations of asthma. It is now largely accepted that there is a wide range of clinical phenotypes of the disease, characterized primarily by small airways involvement. Thus, an appropriate diagnostic algorithm cannot exclude biological and functional assessment of the peripheral airways. Similarly, achievement of optimal control of the disease and appropriate management of specific phenotypes of asthma should be based on drugs (and delivery options) able to distribute uniformly along the bronchial tree and to reach the most peripheral airways. Products developed with the Modulite technology platform have been demonstrated to meet these aims. Recent real-life studies have shown clearly that extra-fine fixed-combination inhaled therapy provides better asthma control than non-extra-fine formulations, thus translating the activity of the drugs into greater effectiveness in clinical practice. We suggest that in patients with incomplete asthma control despite good lung function, involvement of the peripheral airways should always be suspected. When this is the case, treatments targeting both the large and small airways should be used to improve asthma control. Above all, it is emphasized that patient adherence with prescribed medications can contribute to clinical success, and clinicians should always be aware of the role played by patients themselves in determining the success or failure of treatment.
Anti-inflammatory effects of pre-seasonal Th1-adjuvant vaccine to Parietaria judaica in asthmatics
Scichilone N, Minaldi C, Santagata R, Battaglia S, Camarda G, Bellia V
Journal of Asthma and Allergy , 2011, DOI: http://dx.doi.org/10.2147/JAA.S17784
Abstract: nti-inflammatory effects of pre-seasonal Th1-adjuvant vaccine to Parietaria judaica in asthmatics Original Research (3568) Total Article Views Authors: Scichilone N, Minaldi C, Santagata R, Battaglia S, Camarda G, Bellia V Published Date March 2011 Volume 2011:4 Pages 19 - 25 DOI: http://dx.doi.org/10.2147/JAA.S17784 Nicola Scichilone, Chiara Minaldi, Roberta Santagata, Salvatore Battaglia, Gaetana Camarda, Vincenzo Bellia Dipartimento Biomedico di Medicina Interna e Specialistica (Di.Bi.M.I.S.), Sezione di Pneumologia, University of Palermo, Palermo, Italy Background: The ultra-short course pre-seasonal allergy vaccine, containing appropriate allergoids with the adjuvant monophosphoryl lipid A (MPL), may be effective in treating allergic symptoms. Objective: To explore the timing of the immunological responses to the pre-seasonal allergy vaccine. Methods: Four subcutaneous injections of the active product (Pollinex Quattro) were administered to 20 Parietaria-sensitive intermittent asthmatics (M/F: 12/8; age: 48 ± 10 years; FEV1% predicted: 108% ± 12%) during the 6 weeks prior to the start of the pollen season. Exhaled breath condensate (EBC) was collected immediately before the first and immediately after the last injections (t1 and t2), during the pollen season (t3) and after (t4) the pollen season. EBC was analyzed to determine the levels of pH and 8-isoprostane. Ten Parietaria-sensitive asthmatics served as the untreated control group at t1 and t2. Results: Measured pH levels were 7.64 ± 0.33 at t1, 7.67 ± 0.23 at t2, 7.72 ± 0.34 at t3, and 7.82 ± 0.34 at t4 (P = 0.049 vs baseline). 8-isoprostane levels were significantly lower than baseline at each visit (mean difference from baseline, for t2: —0.77 pg, P = 0.031; for t3: —0.92 pg, P = 0.010; for t4: —0.70 pg, P = 0.048). In the control group, pH levels were 7.73 ± 0.26 at baseline and did not change after 6 weeks (7.79 ± 0.25, P = 0.33). Similarly, the concentrations of 8-isoprostane in the control group were not different from those of the study group at baseline (P = 0.86), and the levels remained unchanged after 6 weeks (P = 0.58). Conclusion: These findings show that the ultra-short course of vaccine adjuvated with MPL acutely reduces the degree of airway inflammation, as expressed by markers of oxidative stress, and suggest that this reduction is maintained during and after the pollen season.
Diagnosis of airway obstruction in the elderly: contribution of the SARA study
Sorino C, Battaglia S, Scichilone N, Pedone C, Antonelli-Incalzi R, Sherrill D, Bellia V
International Journal of Chronic Obstructive Pulmonary Disease , 2012, DOI: http://dx.doi.org/10.2147/COPD.S31630
Abstract: gnosis of airway obstruction in the elderly: contribution of the SARA study Original Research (2189) Total Article Views Authors: Sorino C, Battaglia S, Scichilone N, Pedone C, Antonelli-Incalzi R, Sherrill D, Bellia V Published Date June 2012 Volume 2012:7 Pages 389 - 395 DOI: http://dx.doi.org/10.2147/COPD.S31630 Received: 09 March 2012 Accepted: 15 April 2012 Published: 27 June 2012 Claudio Sorino,1,2 Salvatore Battaglia,1 Nicola Scichilone,1 Claudio Pedone,3 Raffaele Antonelli-Incalzi,3 Duane Sherrill,4 Vincenzo Bellia1 1Biomedical Department of Internal and Specialist Medicine, Section of Pulmonology, University of Palermo, Italy; 2Division of Pulmonology, S Anna Hospital, Como, Italy; 3Chair of Geriatrics, University Campus Bio-Medico, Roma, Italy; 4Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, USA Background: The choice between lower limit of normal or fixed value of forced expiratory volume in one second/forced vital capacity ratio (FEV1/FVC) < 0.70 as the criterion for confirming airway obstruction is an open issue. In this study, we compared the criteria of lower limit of normal and fixed FEV1/FVC for diagnosis of airway obstruction, with a focus on healthy elderly people. Methods: We selected 367 healthy nonsmoking subjects aged 65–93 years from 1971 participants in the population-based SARA (Salute Respiratoria nell’Anziano, Italian for “Respiratory Health in the Elderly”) study, analyzed their spirometric data, and tested the relationship between spirometric indices and anthropometric variables. The lower limit of normal for FEV1/FVC was calculated as the fifth percentile of the normal distribution for selected subjects. Results: While FEV1 and FVC decreased significantly with aging, the relationship between FEV1/FVC and age was not statistically significant in men or women. The lower limit of normal for FEV1/FVC was 0.65 in men and 0.67 in women. Fifty-five participants (15%) had FEV1/FVC < 0.70 and would have been inappropriately classified as obstructed according to the Global Initiative for Obstructive Lung Disease, American Thoracic Society/European Respiratory Society, and Canadian guidelines on chronic obstructive pulmonary disease. By applying different FEV1/FVC thresholds for the different age groups, as previously proposed in the literature, (0.70 for <70 years, 0.65 for 70–80 years, and 0.60 for >80 years) the percentage of patients classified as obstructed decreased to 6%. No subjects older than 80 years had an FEV1/FVC < 0.60. Conclusion: The present results confirm the inadequacy of FEV1/FVC < 0.70 as a diagnostic criterion for airway obstruction after the age of 65 years. FEV1/FVC < 0.65 and <0.67 (for men and women, respectively) could identify subjects with airway obstruction in such a population. Further reduction of the threshold after 80 years is not justified.
Lung penetration and patient adherence considerations in the management of asthma: role of extra-fine formulations
Scichilone N, Spatafora M, Battaglia S, Arrigo R, Benfante A, Bellia V
Journal of Asthma and Allergy , 2013, DOI: http://dx.doi.org/10.2147/JAA.S44293
Abstract: Lung penetration and patient adherence considerations in the management of asthma: role of extra-fine formulations Corrigendum (71) Total Article Views Authors: Scichilone N, Spatafora M, Battaglia S, Arrigo R, Benfante A, Bellia V Published Date March 2013 Volume 2013:6 Pages 41 - 42 DOI: http://dx.doi.org/10.2147/JAA.S44293 Received: 20 February 2013 Accepted: 20 February 2013 Published: 20 March 2013 Corrigendum Scichilone N, Spatafora M, Battaglia S, Arrigo R, Benfante A, Bellia V. J Asthma Allergy. 2013;6:11–21. On page 15, the note in the legend for Figure 3 was incorrectly listed as "The improvement is greater in the extra-fine beclomethasone-formoterol combination group than in the non-extra-fine fluticasone propionate-formoterol group". The correct sentence is "The improvement is greater in the extra-fine beclomethasone-formoterol combination group than in the non-extra-fine fluticasone propionate-salmeterol group". On page 16, there is a missing note for Figure 4. Note: Data on file. (Chiesi Farmaceutici S.p.A, 2012) Read the original article Post to: Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter Other articles by Professor Nicola Scichilone Anti-inflammatory effects of pre-seasonal Th1-adjuvant vaccine to Parietaria judaica in asthmatics Lung penetration and patient adherence considerations in the management of asthma: role of extra-fine formulations Patient perspectives in the management of asthma: improving patient outcomes through critical selection of treatment options Readers of this article also read: Lung penetration and patient adherence considerations in the management of asthma: role of extra-fine formulations COPD patient satisfaction with ipratropium bromide/albuterol delivered via Respimat: a randomized, controlled study Effects of regenerative radioelectric asymmetric conveyer treatment on human normal and osteoarthritic chondrocytes exposed to IL-1β. A biochemical and morphological study A comparison of cardiovascular risk factors for ten antipsychotic drugs in clinical practice Complications of vision loss and ophthalmoplegia during endoscopic sinus surgery Sex differences in the relationship between maternal fear of pain and children's conditioned pain modulation Correlation between the modified Kupperman Index and the Menopause Rating Scale in Chinese women
Therapeutical approach to plasma homocysteine and cardiovascular risk reduction
Marcello Ciaccio,Giulia Bivona,Chiara Bellia
Therapeutics and Clinical Risk Management , 2008,
Abstract: Marcello Ciaccio, Giulia Bivona, Chiara BelliaDepartment of Medical Biotechnologies and Forensic Medicine, Faculty of Medicine, University of Palermo, ItalyAbstract: Homocysteine is a sulfur-containing aminoacid produced during metabolism of methionine. Since 1969 the relationship between altered homocysteine metabolism and both coronary and peripheral atherotrombosis is known; in recent years experimental evidences have shown that elevated plasma levels of homocysteine are associated with an increased risk of atherosclerosis and cardiovascular ischemic events. Several mechanisms by which elevated homocysteine impairs vascular function have been proposed, including impairment of endothelial function, production of reactive oxygen species (ROS) and consequent oxidation of low-density lipids. Endothelial function is altered in subjects with hyperhomocysteinemia, and endothelial dysfunction is correlated with plasma levels of homocysteine. Folic acid and B vitamins, required for remethylation of homocysteine to methionine, are the most important dietary determinants of homocysteine and daily supplementation typically lowers plasma homocysteine levels; it is still unclear whether the decreased plasma levels of homocysteine through diet or drugs may be paralleled by a reduction in cardiovascular risk.Keywords: homocysteine, MTHFR, cardiovascular disease, folate, B vitamin
Cyclosporine and Herbal Supplement Interactions
D. Colombo,L. Lunardon,G. Bellia
Journal of Toxicology , 2014, DOI: 10.1155/2014/145325
Abstract: Cyclosporine (CyA) is a well-known immunosuppressant with a narrow therapeutic window. Its bioavailability is affected by many other traditional drugs and herbal extracts. Cytochrome P-450 isoenzymes CYP3A4 and CYP3A5 and protein P-glycoprotein (P-gp) are involved in CyA bioavailability. Interactions of CyA with herbal extracts are not well known, but, given their increased concomitant use, it is important to know which extracts, many of which are commonly self-prescribed, can affect CyA blood concentrations. Decreased CyA blood concentration has been shown with St John’s wort in case reports and, in vivo animal studies, with ginger, liquorice, scutellariae radix, and quercetin. Increased CyA concentration has been reported in patients with grapefruit juice, chamomile, or berberine, and with cannabidiol or resveratrol in animal studies. Effects of Echinacea and Serenoa repens on CyA levels have not been shown consistently, but concomitant use should be avoided. Although findings from animal studies cannot be directly translated into humans, avoiding concomitant use of herbal extracts is prudent until human clinical studies have ruled out any possible interaction. Clinicians should interview their patients carefully about their use of herbal supplements before CyA administration, and those receiving CyA should be warned about possible interactions between herbal preparations and CyA. 1. Introduction In 1972, cyclosporine (CyA) was discovered and identified as a new antifungal drug with unexpected immunologic characteristics. Subsequently, the effect of CyA on lymphocyte activation was demonstrated [1]. Since this discovery, CyA was introduced as a new immunosuppressant therapy and, in the last three decades, has been widely used in transplant recipients to prevent rejection and in the treatment of autoimmune diseases, with successful results. CyA is also widely used in the treatment of psoriasis, atopic dermatitis, and other dermatological disorders. CyA is a lipophilic cyclic polypeptide that selectively inhibits the adaptive immune response. This activity is exerted through CyA binding to cyclophilin, inhibition of calcineurin, and nuclear factor transcription, with a subsequent alteration in T-cell activation. The lipophilic nature of CyA required the development of a triphasic microemulsion preparation with higher hydrophilicity to reduce the interindividual variability in intestinal absorption. CyA is metabolized in the liver and small intestine by isoenzymes CYP3A4 and CYP3A5 of the cytochrome P-450 family [2]. Protein P-glycoprotein (P-gp), an
Hyperhomocysteinemia in Patients with Cognitive Impairment
Marcello Ciaccio,Giulia Bivona,Antonino Tuttolomondo,Chiara Bellia
Research Journal of Biological Sciences , 2008,
Abstract: Cognitive impairment is common in elderly people and represents clinical feature of neurodegenerative diseases. Not all of patients with Mild Cognitive Impairment (MCI) finally develop dementia and it is interesting to investigate the role of possible markers for early diagnosis. Hyperhomocysteinemia is associated to several pathologies including cognitive impairment; aim of this study is to evaluate the correlation between cognitive performance assessment and homocysteine plasma levels. Total 74 patients and 75 healthy controls were enrolled and MCI were defined by a MMSE score lower than 26 after adjustment for years of schooling. Homocysteine plasma levels were determined. Homocysteine levels significantly raised in patients with cognitive impairment and showed a significant negative association with MMSE score. Finally, our data show that a moderate risk of cognitive impairment could be associated to high homocysteine plasma levels.
Plasminogen Activator Inhibitor-1-675 4G/5G and Methylenetetrahydrofolate Reductase Gene Variants in Young Acute Myocardial Infarction and Juvenile Ischemic Stroke
Giulia Bivona,Chiara Bellia,Salvatore Cammarieri,Bruna Lo Sasso
Research Journal of Biological Sciences , 2008,
Abstract: Cardiovascular diseases often recognize a hereditary-familial genetic risk patterns and a substantial proportion of variability in clinical features of atherosclerosis could probably be explained by genetic factors. Aim of this study is to compare prevalence of factor V Leiden, factor II 20210A, PAI-1-675 4G/5G and MTHFR C677T gene variants in 2 cardiovascular disease clinical features: young acute myocardial infarction (<50 years) and ischemic stroke. Plasminogen Activator Inhibitor-1-675 4G/5G didn`t show significant difference between patients and controls while, between patient groups, the polymorphism was most present in myocardial infarction group than in juvenile stroke. Polymorphisms in Homocysteine metabolism: MTHFR C677T variants was significantly higher in patients with myocardial infarction compared with those affected by ischemic Stroke.
Page 1 /130400
Display every page Item


Home
Copyright © 2008-2017 Open Access Library. All rights reserved.